Immunotherapy with anti-PSMA x anti-CD3 bispecific antibody stimulates potent killing of a human prostate cancer cell line and target mediated T cell activation in monkeys: A potential therapy for prostate cancer

被引：1
|
作者：
Chu, Seung Y.
Pong, Erik W. K.
Rashid, Rumana
Chen, Hsing
Chan, Emily W.
Phung, Sheryl
Endo, Nancy A.
Ardila, Maria C.
Bonzon, Christine
Leung, Irene W. L.
Muchhal, Umesh S.
Moore, Gregory L.
Bernett, Matthew J.
Desjarlais, John R.
Szymkowski, David E.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-5000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5000
引用
收藏
页数：4
相关论文
共 50 条
  • [31] QLS31904: An anti-DLL3/CD3 bispecific antibody for T cell immunotherapy of small cell lung cancer
    Yang, Liuqing
    Li, Ruimei
    Jiang, Jiahua
    Qian, Hongliang
    Ge, Hongxiu
    Lu, Ting
    Fang, Yan
    Liu, Jun
    Zhao, Shuyong
    CANCER RESEARCH, 2022, 82 (12)
  • [32] Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
    Yankelevich, Maxim
    Kondadasula, Sri Vidya
    Thakur, Archana
    Buck, Steven
    Cheung, Nai-Kong V.
    Lum, Lawrence G.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (07) : 1198 - 1205
  • [33] Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody.
    Lum, Lawrence G.
    Choi, Minsig
    Tri Minh Le
    Thakur, Archana
    Deol, Abhinav
    Ballen, Karen K.
    Volodin, Leonid
    Kindwall-Keller, Tamila L.
    Liu, Qin
    Dyson, Gregory
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Phase I immunotherapy in women with metastatic breast cancer with activated T cells targeted with anti-CD3 x anti-Her2/neu bispecific antibody
    Lum, L. G.
    Al-Kadhimi, Z.
    Skuba, C.
    Sandborg, R.
    Rathore, R.
    Liu, Q.
    Uberti, J. P.
    Ratanatharathorn, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Combining anti-CD3 activated T cells armed with anti-CD3 x anti-Her2 bispecific antibody may provide an additional anti-tumor effect after stem cell transplant for breast cancer.
    Sen, M
    Wankowski, DM
    Lum, LG
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 743 - 743
  • [36] Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
    Vaishampayan, Ulka N.
    Thakur, Archana
    Chen, Wei
    Deol, Abhinav
    Patel, Meera
    Dobson, Kimberlee
    Dickow, Brenda
    Schalk, Dana
    Schienschang, Amy
    Whitaker, Sarah
    Polend, Amanda
    Fontana, Joseph A.
    Heath, Elisabeth I.
    Lum, Lawrence G.
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 122 - 133
  • [37] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody III.: Kinetics and survival of armed ATC in prostate cancer patients.
    Rathore, R
    Colvin, GA
    Kouttab, NM
    Falvey, MT
    Grabert, RC
    Smith, JA
    Tiggs, JC
    Cohen, IC
    Maizel, AL
    Quesenberry, PJ
    Elfenbein, GJ
    Lum, LG
    BLOOD, 2002, 100 (11) : 54B - 54B
  • [38] Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo
    Han, Huamin
    Ma, Juan
    Zhang, Keming
    Li, Wei
    Liu, Changzhen
    Zhang, Yu
    Zhang, Ganlin
    Ma, Pan
    Wang, Lei
    Zhang, Ge
    Tao, Hua
    Gao, Bin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2446 - 2454
  • [39] Anti-CD3 x anti-EGFR bispecific antibody armed T cells (EGFR BATs) kills resistant pancreatic cancer cell lines and increases sensitivity to chemotherapy
    Lum, Lawrence G.
    Ung, Johnson
    Thakur, Archana
    CANCER RESEARCH, 2019, 79 (13)
  • [40] ROLE OF T-CELL SUBSETS IN THE BISPECIFIC ANTIBODY (ANTIIDIOTYPE X ANTI-CD3) TREATMENT OF THE BCL(1) LYMPHOMA
    DEMANET, C
    BRISSINCK, J
    LEE, O
    MOSER, M
    THIELEMANS, K
    CANCER RESEARCH, 1994, 54 (11) : 2973 - 2978
12345